CY1124222T1 - Ενωσεις πυριδινονης-πυριδινυλιου υποκατεστημενες με μεθυλο/φθορο-πυριδινυλο-μεθοξυ και ενωσεις πυριδινονης-πυριδινυλιου υποκατεστημενες με φθορο-πυριδινυλο-μεθοξυ - Google Patents

Ενωσεις πυριδινονης-πυριδινυλιου υποκατεστημενες με μεθυλο/φθορο-πυριδινυλο-μεθοξυ και ενωσεις πυριδινονης-πυριδινυλιου υποκατεστημενες με φθορο-πυριδινυλο-μεθοξυ

Info

Publication number
CY1124222T1
CY1124222T1 CY20211100281T CY211100281T CY1124222T1 CY 1124222 T1 CY1124222 T1 CY 1124222T1 CY 20211100281 T CY20211100281 T CY 20211100281T CY 211100281 T CY211100281 T CY 211100281T CY 1124222 T1 CY1124222 T1 CY 1124222T1
Authority
CY
Cyprus
Prior art keywords
pyridinyl
compounds
fluoro
methoxy
substituted pyridinone
Prior art date
Application number
CY20211100281T
Other languages
English (en)
Inventor
Susan L. Hockerman
Joseph B. Monahan
Shaun R. Selness
Original Assignee
Aclaris Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aclaris Therapeutics, Inc. filed Critical Aclaris Therapeutics, Inc.
Publication of CY1124222T1 publication Critical patent/CY1124222T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms

Abstract

Η παρούσα εφεύρεση παρέχει μεθυλο/φθορο-πυριδινυλο-μεθοξυ υποκατεστημένες ενώσεις πυριδινόνης-πυριδινυλίου και φθορο-πυριμιδινυλο-μεθοξυ υποκατεστημένες ενώσεις πυριδινόνης-πυριδινυλίου χρήσιμες στην αγωγή νόσων που διαμεσολαβούνται από κινάση p38, όπως το λέμφωμα και μία αυτοφλεγμονώδης νόσος, συμπεριλαμβανομένης της ρευματοειδούς αρθρίτιδας, οι οποίες έχουν τη δομή του Τύπου (Ι) όπου R1, R2, R3, R4, R5, και Χ είναι όπως ορίζονται στη λεπτομερή περιγραφή' φαρμακευτικές συνθέσεις που περιέχουν τουλάχιστον μία από τις ενώσεις' και μεθόδους για την αγωγή νόσων που διαμεσολαβούνται από κινάση p38 διά της χρήσης των ενώσεων.
CY20211100281T 2013-06-07 2021-03-31 Ενωσεις πυριδινονης-πυριδινυλιου υποκατεστημενες με μεθυλο/φθορο-πυριδινυλο-μεθοξυ και ενωσεις πυριδινονης-πυριδινυλιου υποκατεστημενες με φθορο-πυριδινυλο-μεθοξυ CY1124222T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361832736P 2013-06-07 2013-06-07
PCT/US2014/041381 WO2014197846A1 (en) 2013-06-07 2014-06-06 Methyl/fluoro-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds and fluoro-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds

Publications (1)

Publication Number Publication Date
CY1124222T1 true CY1124222T1 (el) 2022-05-27

Family

ID=52005972

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100281T CY1124222T1 (el) 2013-06-07 2021-03-31 Ενωσεις πυριδινονης-πυριδινυλιου υποκατεστημενες με μεθυλο/φθορο-πυριδινυλο-μεθοξυ και ενωσεις πυριδινονης-πυριδινυλιου υποκατεστημενες με φθορο-πυριδινυλο-μεθοξυ

Country Status (17)

Country Link
US (2) US9115089B2 (el)
EP (2) EP3845529A1 (el)
JP (4) JP6699909B2 (el)
KR (3) KR102470598B1 (el)
CN (2) CN108478579B (el)
CA (1) CA2917344C (el)
CY (1) CY1124222T1 (el)
DK (1) DK3003039T3 (el)
ES (1) ES2869048T3 (el)
HR (1) HRP20210813T1 (el)
HU (1) HUE054178T2 (el)
LT (1) LT3003039T (el)
PL (1) PL3003039T3 (el)
PT (1) PT3003039T (el)
RS (1) RS61724B1 (el)
SI (1) SI3003039T1 (el)
WO (1) WO2014197846A1 (el)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3003039T (pt) * 2013-06-07 2021-03-04 Aclaris Therapeutics Inc Compostos piridinona-piridinilo substituídos com metil/fluoro-piridinil-metoxilo e compostos piridinona-pirimidinilo substituídos com fluoro-pirimidinil-metoxilo
EP3502692A1 (en) 2017-12-20 2019-06-26 Aposcience AG Potency assay for secretomes
BR112022001324A2 (pt) * 2019-07-31 2022-03-22 Aclaris Therapeutics Inc Composto, composição farmacêutica e método para tratamento de uma doença mediada por p38 map quinase em um indivíduo necessitando do mesmo
MX2022011748A (es) * 2020-03-27 2022-12-02 Aclaris Therapeutics Inc Composiciones orales de inhibidor de ruta de mk2 para el tratamiento de condiciones inmunitarias.
CA3198300A1 (en) * 2020-11-23 2022-05-27 Gary A. Decrescenzo Methods of synthesizing substituted pyridinone-pyridinyl compounds
EP4313970A1 (en) 2021-03-31 2024-02-07 Xinthera, Inc. Mk2 inhibitors and uses thereof
US11685719B2 (en) 2021-07-09 2023-06-27 Xinthera, Inc. Pyridinone MK2 inhibitors and uses thereof
WO2023001282A1 (zh) * 2021-07-23 2023-01-26 南京明德新药研发有限公司 杂环取代的嘧啶衍生物
TW202315625A (zh) * 2021-08-13 2023-04-16 大陸商深圳信立泰藥業股份有限公司 三聯吡啶二酮化合物或其鹽、包括其藥物組合物及其用途
WO2023125707A1 (zh) * 2021-12-29 2023-07-06 上海美悦生物科技发展有限公司 一种p38 MAPK/MK2通路调节剂及其组合物、制备方法和用途
CN116354935A (zh) * 2021-12-29 2023-06-30 上海美悦生物科技发展有限公司 一种p38 MAPK/MK2通路调节剂及其组合物、制备方法和用途
WO2023134765A1 (zh) * 2022-01-14 2023-07-20 上海翰森生物医药科技有限公司 含五元环类衍生物、其制备方法和应用
WO2023150709A2 (en) * 2022-02-04 2023-08-10 Aclaris Therapeutics, Inc. Methods of synthesizing deuterated substituted pyridinone-pyridinyl compounds
WO2023165554A1 (zh) * 2022-03-03 2023-09-07 深圳信立泰药业股份有限公司 一种氘代三联吡啶二酮化合物或其盐及其制备方法与应用
CN115057811A (zh) * 2022-05-26 2022-09-16 安庆朗坤药业有限公司 一种2-溴甲基-3,5-二氟吡啶的制备方法
WO2024022412A1 (zh) * 2022-07-28 2024-02-01 深圳信立泰药业股份有限公司 一种式(i)所示的三联吡啶二酮化合物晶型及其制备方法与应用
WO2024046327A1 (zh) * 2022-08-30 2024-03-07 长春金赛药业有限责任公司 p38α-MK2抑制剂化合物、药物组合物及其应用
WO2024077059A1 (en) * 2022-10-05 2024-04-11 Xinthera, Inc. Crystalline forms of an mk2 inhibitor

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US789061A (en) * 1904-07-11 1905-05-02 Harrison G Post Paper barrel.
JP2002526482A (ja) 1998-09-18 2002-08-20 バーテックス ファーマシューティカルズ インコーポレイテッド ｐ３８のインヒビター
BR0011274A (pt) 1999-05-21 2002-02-26 Scios Inc Derivados tipo indol como inibidores de p38 quinase
US6821966B2 (en) 2000-11-20 2004-11-23 Scios, Inc. Inhibitors of p38 kinase
US7314752B2 (en) 2001-07-19 2008-01-01 Common Sense, Ltd. Secretion-monitoring article
GEP20063937B (en) 2002-02-14 2006-10-10 Pharmacia Corp Substituted pyridinones as modulators of p38 map kinase
US7304061B2 (en) 2002-04-26 2007-12-04 Vertex Pharmaceuticals Incorporated Heterocyclic inhibitors of ERK2 and uses thereof
GB0218630D0 (en) 2002-08-10 2002-09-18 Tanabe Seiyaku Co Novel compounds
CA2498111A1 (en) 2002-09-11 2004-03-25 Merck & Co., Inc. Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors
US7183287B2 (en) 2003-04-03 2007-02-27 Pharmacia Corporation Substituted pyrimidinones
US20070167621A1 (en) 2003-04-03 2007-07-19 Pharmacia Corporation Substituted pyrimidinones
NL1026826C2 (nl) 2003-08-13 2007-01-04 Pharmacia Corp Gesubstitueerde pyridinonen.
JP2005255675A (ja) 2004-02-09 2005-09-22 Tanabe Seiyaku Co Ltd 医薬組成物
MXPA06009132A (es) 2004-02-11 2007-03-26 Smithkline Beecham Corp Inhibidores de integrasa de vih.
US7576212B2 (en) 2004-12-09 2009-08-18 Xention Limited Thieno[2,3-B] pyridines as potassium channel inhibitors
EP1875912A4 (en) 2005-04-08 2008-06-04 Eisai R&D Man Co Ltd MEANS OF TREATING UNWILLING MOVEMENTS
WO2007006591A2 (fr) 2005-07-13 2007-01-18 Bayer Cropscience Sa Dihalogenation d'hydroxipyridones n,o-disubstituees et leurs utilisations
WO2007081901A2 (en) 2006-01-05 2007-07-19 The Scripps Research Institute Pyrimidinone derivatives as protein kinase inhibitors
UY30378A1 (es) 2006-06-02 2008-01-02 Janssen Pharmaceutica Nv Nuevos derivados de piridinona n-aril y n-heteroaril sustituidos para usar en enfermedades mediadas por mch-1
CA2656535C (en) * 2006-07-14 2011-08-23 Amgen Inc. Alkyne-substituted pyridone compounds and methods of use
EA200970510A1 (ru) 2006-11-24 2009-12-30 Такеда Фармасьютикал Компани Лимитед Гетеромоноциклическое соединение и его применение
CA2670728A1 (en) 2006-12-07 2008-06-19 Novartis Ag Pyridine derivatives used as xiap inhibitors
US8198276B2 (en) 2007-06-06 2012-06-12 Xcovery Holding Company Llc Kinase inhibitor compounds
PE20090449A1 (es) 2007-07-17 2009-04-18 Bristol Myers Squibb Co Agonistas de receptor acoplado a proteina g gpr119 de piridona
SG192439A1 (en) 2008-06-27 2013-08-30 Novartis Ag Organic compounds
US8629158B2 (en) 2009-07-01 2014-01-14 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
WO2011003012A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof
US9073925B2 (en) 2009-07-01 2015-07-07 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
DK2648516T3 (da) * 2010-12-06 2019-01-02 Aclaris Therapeutics Inc Substituerede pyridinon-pyridinylforbindelser
WO2013086208A1 (en) * 2011-12-06 2013-06-13 Confluence Life Sciences, Inc. Substituted pyrimidinone-phenyl-pyrimidinyl compounds
PT3003039T (pt) * 2013-06-07 2021-03-04 Aclaris Therapeutics Inc Compostos piridinona-piridinilo substituídos com metil/fluoro-piridinil-metoxilo e compostos piridinona-pirimidinilo substituídos com fluoro-pirimidinil-metoxilo
USD789061S1 (en) * 2015-11-04 2017-06-13 Salomon S.A.S. Upper of a footwear article

Also Published As

Publication number Publication date
KR102313515B1 (ko) 2021-10-14
KR20220158853A (ko) 2022-12-01
JP6838796B2 (ja) 2021-03-03
HRP20210813T1 (hr) 2021-06-25
WO2014197846A1 (en) 2014-12-11
ES2869048T3 (es) 2021-10-22
RS61724B1 (sr) 2021-05-31
JP2022180524A (ja) 2022-12-06
JP2016520654A (ja) 2016-07-14
US20150352092A1 (en) 2015-12-10
CA2917344C (en) 2021-09-07
US20140364442A1 (en) 2014-12-11
EP3003039A1 (en) 2016-04-13
HUE054178T2 (hu) 2021-08-30
KR20210126158A (ko) 2021-10-19
KR102653785B1 (ko) 2024-04-01
US9115089B2 (en) 2015-08-25
JP2020075930A (ja) 2020-05-21
CN105263326B (zh) 2018-06-22
JP6699909B2 (ja) 2020-05-27
CN108478579B (zh) 2021-05-25
EP3003039A4 (en) 2017-04-19
JP2021073302A (ja) 2021-05-13
EP3845529A1 (en) 2021-07-07
EP3003039B1 (en) 2021-02-24
PL3003039T3 (pl) 2021-10-25
KR20160017073A (ko) 2016-02-15
PT3003039T (pt) 2021-03-04
CN108478579A (zh) 2018-09-04
DK3003039T3 (da) 2021-05-25
JP7146968B2 (ja) 2022-10-04
KR102470598B1 (ko) 2022-11-23
US9636333B2 (en) 2017-05-02
CN105263326A (zh) 2016-01-20
LT3003039T (lt) 2021-05-10
SI3003039T1 (sl) 2021-08-31
CA2917344A1 (en) 2014-12-11

Similar Documents

Publication Publication Date Title
CY1124222T1 (el) Ενωσεις πυριδινονης-πυριδινυλιου υποκατεστημενες με μεθυλο/φθορο-πυριδινυλο-μεθοξυ και ενωσεις πυριδινονης-πυριδινυλιου υποκατεστημενες με φθορο-πυριδινυλο-μεθοξυ
CY1120834T1 (el) Δικυκλικες αζωτουχες ενωσεις ως αγωνιστες μουσκαρινικων υποδοχεων μ1
CY1122560T1 (el) Νεα παραγωγα αμμωνιου, μεθοδος για παρασκευη αυτων και φαρμακευτικες συνθεσεις που περιεχουναυτα
CY1123349T1 (el) Ενωσεις 6-ετεροκυκλυλ-4-μορφολιν-4-υλπυρiδιν-2-οnhς χρησιμες για τη θεραπεια καρκινου και διαβητη
CY1122821T1 (el) Παραγωγα 1,3-βενζοδιοξολιου ως αναστολεις εζη1 ή/και εζη2
CY1121804T1 (el) Καινοτομες ενωσεις πυριμιδινης και πυριδινης και η χρηση τους
CY1124798T1 (el) Υποκατεστημενα παραγωγα καρβονουκλεοζιδιων χρησιμα ως παραγοντες κατα των καρκινων
CY1123069T1 (el) Νεα (ετερο)αρυλ-υποκατεστημενα-πιπεριδινυλ παραγωγα, μεθοδος για παρασκευη αυτων και φαρμακευτικες συνθεσεις που περιεχουν αυτα
CY1122065T1 (el) Ενωσεις αλκυλ-αμιδο-υποκατεστημενου πυριδυλιου χρησιμες ως διαμορφωτες των αποκρισεων il-12, il-23 και/η ιfναλφα
CY1120635T1 (el) Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης
CY1122776T1 (el) Επιλεκτικως υποκατεστημενες ενωσεις κινολινης
CY1124638T1 (el) Ενωσεις κυκλικων δινουκλεοτιδιων
CY1121195T1 (el) Παραγωγα τετραϋδροναφθαλενιου που αναστελλουνπρωτεϊνη mcl-1
CY1122870T1 (el) Νεα πιπεριδινυλ παραγωγα, μεθοδος για παρασκευη αυτων και φαρμακευτικες συνθεσεις που τα περιεχουν
CY1119707T1 (el) Ενωσεις διαρυλικου αμιδιου ως αναστολεις της κινασης
CY1123645T1 (el) Δικυκλικα παραγωγα, μεθοδος για παρασκευη αυτων και φαρμακευτικες συνθεσεις που περιεχουν αυτα
CY1124407T1 (el) Ενωσεις αναστολεα αυτοταξινης
CY1121468T1 (el) Συνδυασμος παραγωγων πυρρολο[2,3-d]πυριμιδινης με εναν ή περισσοτερους επιπροσθετους παραγοντες ως αναστολεις των σχετικων me janus (ιανος) kinασων (jak)
CY1122695T1 (el) Αλας toy omecamtiv mecarbil και διαδικασια για την παρασκευη αλατος
CY1121938T1 (el) Αγωνιστες apj 4-υδροξυ-3-(ετερο¶ρυλ)πυριδινο-2-ονης για χρηση στη θεραπεια καρδιαγγειακων διαταραχων
CY1119361T1 (el) 3,4-διυδροισοκινολιν-2(1h)-υλικες ενωσεις
CY1124918T1 (el) Ρυθμιστες ccr2
CY1118547T1 (el) Νεα παραγωγα ινδολιζινης, μεθοδος παρασκευης τους και φαρμακευτικες συνθεσεις οι οποιες τα περιεχουν για τη θεραπεια του καρκινου
CY1118416T1 (el) Υποκατεστημενες 4-φαινυλο-πυριδινες για τη θεραπεια ασθενειων που σχετιζονται με τον νκ-1 υποδοχεα
CY1123285T1 (el) Ενωσεις 6-αρυλ-4-(μορφολιν-4-υλ)-1η-πυριδιν-2-ονης χρησιμες για τη θεραπεια καρκινου και διαβητη